Accepted for Publication: August 28, 2020.
Published Online: November 4, 2020. doi:10.1001/jamapsychiatry.2020.3446
Corresponding Author: Victoria Manning, PhD, Turning Point, Eastern Health, 110 Church St, Richmond, VIC 3121, Australia (victoria.manning@monash.edu).
Author Contributions: Dr Reynolds had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Manning, Garfield, Staiger, Lubman, Lum, Reynolds, Hall, Lloyd-Jones, Wiers, Verdejo-Garcia.
Acquisition, analysis, or interpretation of data: Manning, Garfield, Lum, Reynolds, Bonomo, Lloyd-Jones, Piercy, Jacka, Verdejo-Garcia.
Drafting of the manuscript: Manning, Garfield, Lubman, Lum, Reynolds, Lloyd-Jones, Wiers, Piercy.
Critical revision of the manuscript for important intellectual content: Manning, Garfield, Staiger, Lubman, Reynolds, Hall, Bonomo, Lloyd-Jones, Piercy, Jacka, Verdejo-Garcia.
Statistical analysis: Lum, Reynolds.
Obtained funding: Manning, Staiger, Lubman, Lum, Reynolds, Hall, Verdejo-Garcia.
Administrative, technical, or material support: Manning, Garfield, Staiger, Lubman, Lum, Bonomo, Piercy, Jacka.
Supervision: Manning, Piercy.
Conflict of Interest Disclosures: Dr Manning reported receiving grants from the National Health and Medical Research Council (NHMRC) during the conduct of the study. Dr Garfield reported receiving salary support through an NHMRC grant during the conduct of the study. Dr Lubman has provided consultancy advice to Lundbeck and Indivior outside the submitted work; has received travel support and speaker honoraria from AstraZeneca, Camurus, Indivior, Janssen, Lundbeck, Shire, and Servier outside the submitted work; and has been an investigator on an untied education grant from Sequirus unrelated to the current work. Dr Reynolds reported receiving grants from the NHMRC during the conduct of the study, grants from AbbVie outside the submitted work, being a former employee of Novartis AG (2009-2012), and holding shares in Novartis AG and ALCON. Dr Bonomo has received research grants from St Vincent's Health Australia Research Foundation and the NHMRC unrelated to the current work; has received research support from Merck Sharp & Dohme, Victorian Medical Research Acceleration Fund, and Perpetual IMPACT Philanthropy Fund, all unrelated to the current work; has been on advisory boards for Indivior and Seqiris; and is a principal investigator for an industry-sponsored clinical trial of the pharmacokinetics of medicinal cannabis for Zelira Therapeutics unrelated to the current work. Dr Lloyd-Jones reported receiving personal fees from Indivior outside the submitted work. Mr Piercy reported salary support through an NHMRC grant during the conduct of the study. Dr Verdejo-Garcia reported receiving grants from the Australian Medical Research Future Fund and grants from the NHMRC during the conduct of the study, personal fees from Servier and Elsevier outside the submitted work, and being part of the Scientific Advisory Board of Monclarity/Brainwell, which produces cognitive training games, but does not receive any honorarium. No other disclosures were reported.
Funding/Support: This study was funded by grant 1124604 from the NHMRC.
Role of the Funder/Sponsor: The NHMRC had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Sharing Statement: See Supplement 3.
Additional Contributions: We appreciate the work done by research assistants and volunteers in collecting these data who are employed by Monash University and Eastern Health, including Katherine Mroz, JD, Samuel Campbell, MDS, Patrick Haylock, BSc (Hons), Kristina Vujcic, BA, and Nyssa Fergusson, MPH, who received a salary in compensation for their work, and Alexandra Turnbull, BHSc (Hons), a volunteer affiliated with Monash University who did not receive compensation for her involvement. Also included are honors students from the Monash University School of Psychological Sciences: Thomas Tolliday, BA (Hons), and Emily Darmanin, BSc (Hons), who did not receive compensation for supporting this research. We also thank the nursing, administrative, and other staff at the recruitment sites, including but not limited to Angela Fazio, BNurs, and Jennifer Kelly, RN (Depaul House, Saint Vincent’s Hospital Melbourne), Molly O’Reilly, DipSocSc (Windana Drug and Alcohol Recovery), Michelle Cody, Cert IV (Monash Health Community Residential Withdrawal Unit), and Alex Lebani, BSc, Trudy Trice, DipNurs, and Bernadette De Boer (Turning Point, Eastern Health). These staff did not receive compensation for supporting this study. Paul Sanfilippo, PhD, a biostatistician (Monash Addiction Research Centre, Monash University), assisted with statistical analyses and received no compensation beyond his salary for this work.
1.WHO. Global Status Report on Alcohol and Health 2018: Executive Summary. World Health Organization; 2018.
3.Slade
T , Chiu
WT , Glantz
M ,
et al. A cross-national examination of differences in classification of lifetime alcohol use disorder between
DSM-IV and
DSM-5: findings from the World Mental Health Survey.
Alcohol Clin Exp Res. 2016;40(8):1728-1736. doi:
10.1111/acer.13134
PubMedGoogle ScholarCrossref 6.Manning
V , Staiger
PK , Hall
K ,
et al. Cognitive bias modification training during inpatient alcohol detoxification reduces early relapse: a randomized controlled trial.
Alcohol Clin Exp Res. 2016;40(9):2011-2019. doi:
10.1111/acer.13163
PubMedGoogle ScholarCrossref 9.Magill
M , Ray
L , Kiluk
B ,
et al. A meta-analysis of cognitive-behavioral therapy for alcohol or other drug use disorders: treatment efficacy by contrast condition.
J Consult Clin Psychol. 2019;87(12):1093-1105. doi:
10.1037/ccp0000447
PubMedGoogle ScholarCrossref 11.Wiers
RW , Gladwin
TE , Hofmann
W , Salemink
E , Ridderinkhof
KR . Cognitive bias modification and cognitive control training in addiction and related psychopathology: mechanisms, clinical perspectives, and ways forward.
Clin Psychol Sci. 2013;1(2):192-212. doi:
10.1177/2167702612466547
Google ScholarCrossref 12.Eberl
C , Wiers
RW , Pawelczack
S , Rinck
M , Becker
ES , Lindenmeyer
J . Approach bias modification in alcohol dependence: do clinical effects replicate and for whom does it work best?
Dev Cogn Neurosci. 2013;4:38-51. doi:
10.1016/j.dcn.2012.11.002
PubMedGoogle ScholarCrossref 13.Rinck
M , Wiers
RW , Becker
ES , Lindenmeyer
J . Relapse prevention in abstinent alcoholics by cognitive bias modification: clinical effects of combining approach bias modification and attention bias modification.
J Consult Clin Psychol. 2018;86(12):1005-1016. doi:
10.1037/ccp0000321
PubMedGoogle ScholarCrossref 14.Wiers
RW , Eberl
C , Rinck
M , Becker
ES , Lindenmeyer
J . Retraining automatic action tendencies changes alcoholic patients’ approach bias for alcohol and improves treatment outcome.
Psychol Sci. 2011;22(4):490-497. doi:
10.1177/0956797611400615
PubMedGoogle ScholarCrossref 16.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. American Psychiatric Association; 2013.
17.First
MB , Williams
JBW , Karg
RS , Spitzer
RL . User’s Guide for the Structured Clinical Interview for DSM-5 Disorders, Research Version (SCID-5-RV). American Psychiatric Association; 2015.
19.Sobell
LC , Sobell
MB . Timeline Followback User's Guide: A Calendar Method for Assessing Alcohol and Drug Use. Addiction Research Foundation; 1996.
21.LaPlante
DA . Replication is fundamental, but is it common? a call for scientific self-reflection and contemporary research practices in gambling-related research.
Int Gambling Studies. 2019;19(3):362-368. doi:
10.1080/14459795.2019.1672768
Google ScholarCrossref 22.Lubman
DI , Garfield
JBB , Manning
V ,
et al. Characteristics of individuals presenting to treatment for primary alcohol problems versus other drug problems in the Australian patient pathways study.
BMC Psychiatry. 2016;16(1):250. doi:
10.1186/s12888-016-0956-9
PubMedGoogle ScholarCrossref 26.Stahl
SM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 4th ed. Cambridge University Press; 2013.
36.Mann
K , Batra
A , Fauth-Bühler
M , Hoch
E ; the Guideline Group. German guidelines on screening, diagnosis and treatment of alcohol use disorders.
Eur Addict Res. 2017;23(1):45-60. doi:
10.1159/000455841
PubMedGoogle ScholarCrossref 37.Verdejo-Garcia
A , Lorenzetti
V , Manning
V ,
et al. A roadmap for integrating neuroscience into addiction treatment: a consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine.
Front Psychiatry. 2019;10:877. doi:
10.3389/fpsyt.2019.00877
PubMedGoogle ScholarCrossref